vs

Side-by-side financial comparison of FUELCELL ENERGY INC (FCEL) and REGENXBIO Inc. (RGNX). Click either name above to swap in a different company.

FUELCELL ENERGY INC is the larger business by last-quarter revenue ($55.0M vs $30.3M, roughly 1.8× REGENXBIO Inc.). FUELCELL ENERGY INC runs the higher net margin — -54.3% vs -221.3%, a 167.1% gap on every dollar of revenue. On growth, REGENXBIO Inc. posted the faster year-over-year revenue change (43.0% vs 11.5%). FUELCELL ENERGY INC produced more free cash flow last quarter ($-23.9M vs $-52.8M). Over the past eight quarters, FUELCELL ENERGY INC's revenue compounded faster (81.6% CAGR vs 39.4%).

FuelCell Energy, Inc. is a publicly traded fuel cell company headquartered in Danbury, Connecticut. It designs, manufactures, operates and services power plants based on molten carbonate fuel cells.

REGENXBIO Inc. is a clinical-stage biotechnology firm focused on gene therapy for rare severe genetic diseases. It licenses its proprietary AAV vector technology to global biopharma partners, and advances its own pipeline targeting ophthalmology, metabolic and neurodegenerative disorders.

FCEL vs RGNX — Head-to-Head

Bigger by revenue
FCEL
FCEL
1.8× larger
FCEL
$55.0M
$30.3M
RGNX
Growing faster (revenue YoY)
RGNX
RGNX
+31.5% gap
RGNX
43.0%
11.5%
FCEL
Higher net margin
FCEL
FCEL
167.1% more per $
FCEL
-54.3%
-221.3%
RGNX
More free cash flow
FCEL
FCEL
$28.9M more FCF
FCEL
$-23.9M
$-52.8M
RGNX
Faster 2-yr revenue CAGR
FCEL
FCEL
Annualised
FCEL
81.6%
39.4%
RGNX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FCEL
FCEL
RGNX
RGNX
Revenue
$55.0M
$30.3M
Net Profit
$-29.9M
$-67.1M
Gross Margin
-12.1%
Operating Margin
-51.5%
-190.0%
Net Margin
-54.3%
-221.3%
Revenue YoY
11.5%
43.0%
Net Profit YoY
27.9%
-31.2%
EPS (diluted)
$-0.43
$-1.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FCEL
FCEL
RGNX
RGNX
Q4 25
$55.0M
$30.3M
Q3 25
$46.7M
$29.7M
Q2 25
$37.4M
$21.4M
Q1 25
$19.0M
$89.0M
Q4 24
$49.3M
$21.2M
Q3 24
$23.7M
$24.2M
Q2 24
$22.4M
$22.3M
Q1 24
$16.7M
$15.6M
Net Profit
FCEL
FCEL
RGNX
RGNX
Q4 25
$-29.9M
$-67.1M
Q3 25
$-91.7M
$-61.9M
Q2 25
$-38.0M
$-70.9M
Q1 25
$-28.3M
$6.1M
Q4 24
$-41.4M
$-51.2M
Q3 24
$-32.7M
$-59.6M
Q2 24
$-32.1M
$-53.0M
Q1 24
$-19.8M
$-63.3M
Gross Margin
FCEL
FCEL
RGNX
RGNX
Q4 25
-12.1%
Q3 25
-11.0%
Q2 25
-25.2%
Q1 25
-27.4%
Q4 24
-22.1%
70.2%
Q3 24
-26.2%
48.8%
Q2 24
-31.6%
52.5%
Q1 24
-70.2%
72.6%
Operating Margin
FCEL
FCEL
RGNX
RGNX
Q4 25
-51.5%
-190.0%
Q3 25
-204.0%
-176.3%
Q2 25
-95.7%
-296.3%
Q1 25
-172.9%
13.6%
Q4 24
-83.2%
-242.1%
Q3 24
-141.9%
-256.6%
Q2 24
-184.5%
-251.3%
Q1 24
-254.5%
-408.8%
Net Margin
FCEL
FCEL
RGNX
RGNX
Q4 25
-54.3%
-221.3%
Q3 25
-196.1%
-208.3%
Q2 25
-101.7%
-331.8%
Q1 25
-149.1%
6.8%
Q4 24
-84.0%
-241.3%
Q3 24
-137.8%
-246.3%
Q2 24
-143.4%
-237.7%
Q1 24
-118.6%
-405.4%
EPS (diluted)
FCEL
FCEL
RGNX
RGNX
Q4 25
$-0.43
$-1.30
Q3 25
$-3.78
$-1.20
Q2 25
$-1.79
$-1.38
Q1 25
$-1.42
$0.12
Q4 24
$-2.29
$-0.99
Q3 24
$-1.99
$-1.17
Q2 24
$-2.18
$-1.05
Q1 24
$-1.37
$-1.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FCEL
FCEL
RGNX
RGNX
Cash + ST InvestmentsLiquidity on hand
$278.1M
$230.1M
Total DebtLower is stronger
$103.8M
Stockholders' EquityBook value
$662.2M
$102.7M
Total Assets
$932.1M
$453.0M
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FCEL
FCEL
RGNX
RGNX
Q4 25
$278.1M
$230.1M
Q3 25
$174.7M
$274.2M
Q2 25
$177.0M
$323.3M
Q1 25
$208.4M
$267.9M
Q4 24
$257.3M
$234.7M
Q3 24
$267.2M
$255.5M
Q2 24
$260.1M
$290.4M
Q1 24
$297.5M
$338.7M
Total Debt
FCEL
FCEL
RGNX
RGNX
Q4 25
$103.8M
Q3 25
$106.4M
Q2 25
$109.4M
Q1 25
$112.3M
Q4 24
$115.7M
Q3 24
$112.7M
Q2 24
$116.2M
Q1 24
$107.2M
Stockholders' Equity
FCEL
FCEL
RGNX
RGNX
Q4 25
$662.2M
$102.7M
Q3 25
$556.2M
$161.5M
Q2 25
$609.2M
$213.7M
Q1 25
$635.2M
$274.2M
Q4 24
$656.9M
$259.7M
Q3 24
$675.8M
$301.4M
Q2 24
$639.8M
$348.3M
Q1 24
$663.9M
$390.7M
Total Assets
FCEL
FCEL
RGNX
RGNX
Q4 25
$932.1M
$453.0M
Q3 25
$830.5M
$525.2M
Q2 25
$883.8M
$581.0M
Q1 25
$907.5M
$490.9M
Q4 24
$944.1M
$466.0M
Q3 24
$948.9M
$519.1M
Q2 24
$916.8M
$569.4M
Q1 24
$923.2M
$629.2M
Debt / Equity
FCEL
FCEL
RGNX
RGNX
Q4 25
0.16×
Q3 25
0.19×
Q2 25
0.18×
Q1 25
0.18×
Q4 24
0.18×
Q3 24
0.17×
Q2 24
0.18×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FCEL
FCEL
RGNX
RGNX
Operating Cash FlowLast quarter
$-22.9M
$-52.3M
Free Cash FlowOCF − Capex
$-23.9M
$-52.8M
FCF MarginFCF / Revenue
-43.4%
-174.0%
Capex IntensityCapex / Revenue
1.8%
1.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-143.9M
$-126.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FCEL
FCEL
RGNX
RGNX
Q4 25
$-22.9M
$-52.3M
Q3 25
$-26.8M
$-56.0M
Q2 25
$-29.9M
$-49.3M
Q1 25
$-45.7M
$33.6M
Q4 24
$5.8M
$-31.6M
Q3 24
$-63.4M
$-40.5M
Q2 24
$-37.1M
$-45.5M
Q1 24
$-58.3M
$-55.5M
Free Cash Flow
FCEL
FCEL
RGNX
RGNX
Q4 25
$-23.9M
$-52.8M
Q3 25
$-32.1M
$-56.5M
Q2 25
$-35.2M
$-49.7M
Q1 25
$-52.8M
$32.6M
Q4 24
$-4.7M
$-32.7M
Q3 24
$-76.8M
$-40.9M
Q2 24
$-50.3M
$-46.0M
Q1 24
$-68.8M
$-56.0M
FCF Margin
FCEL
FCEL
RGNX
RGNX
Q4 25
-43.4%
-174.0%
Q3 25
-68.6%
-189.9%
Q2 25
-94.0%
-232.8%
Q1 25
-277.8%
36.6%
Q4 24
-9.5%
-154.2%
Q3 24
-324.0%
-168.9%
Q2 24
-224.5%
-206.2%
Q1 24
-412.4%
-358.5%
Capex Intensity
FCEL
FCEL
RGNX
RGNX
Q4 25
1.8%
1.7%
Q3 25
11.2%
1.7%
Q2 25
14.1%
1.8%
Q1 25
37.2%
1.2%
Q4 24
21.4%
5.1%
Q3 24
56.6%
1.3%
Q2 24
58.9%
2.1%
Q1 24
63.3%
3.6%
Cash Conversion
FCEL
FCEL
RGNX
RGNX
Q4 25
Q3 25
Q2 25
Q1 25
5.53×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FCEL
FCEL

Other$30.0M55%
Electricity Generation$12.2M22%
Services$7.3M13%
Advanced Technologies$5.5M10%

RGNX
RGNX

Novartis Gene Therapies$24.2M80%
Nippon Shinyaku Collaboration And License Agreement$4.3M14%
Nippon Shinyaku Services$1.4M5%

Related Comparisons